SG's MiRXES raises $77m Series C round led by CR-CP Life Science Fund

SG's MiRXES raises $77m Series C round led by CR-CP Life Science Fund

Singapore-based biotechnology company MiRXES has raised $77 million in Series C funding led by CR-CP Life Science Fund, a joint venture between China Resources Group and Thailand’s Charoen Pokphand Group.

According to a statement, the round was also joined by global healthcare investment firm Rock Springs Capital and Singapore-based global investor EDBI, CCBI, Keytone Ventures, and  financial institutions from the US, Singapore, China, Hong Kong and others.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter